Stent Tek Limited

Life Sciences
Catheter Technology
Aim of funding: 
HMRC Advance Assurance received: 

Stent Tek Limited


The Company is developing a novel catheter system that enables patients to receive haemodialysis (‘HD’) in an improved manner. Currently, patients receiving HD must undergo a surgical procedure to create a surgical connection between an artery and a vein, the vein then acts as a ‘vascular access’ through which a dialysis machine is connected. The surgical connection between the vein and artery is known as an ‘arteriovenous fistula’.  At present, there are more than 2.5 million patients world-wide who require HD due to renal failure. Fistulas, whilst an established technology, are unreliable often blocking up and requiring repeated costly repair operations. In short, the patient’s life is dependent upon dialysis, and the dialysis is dependent upon a fully functioning fistula.

The Company has developed a minimally invasive procedure that uses a ‘stent graft’ (in effect, a synthetic tube) to form the fistula which is then inserted using a proprietary technology named ePATH), a process that is significantly less traumatic than surgery. The resulting fistula is ready in a shorter timeframe and less likely to fail, thus resulting in fewer patients suffering secondary infection and potentially life-threatening medical complications.


The Company has identified a number of potential revenue streams:

  • Direct sales of its ePATH device;
  • Direct sales of its proprietary stent grafts to use in conjunction with the ePATH device;
  • Licensing of intellectual property; and
  • The sale of a defined list of peripherals and replacement parts.

Within the UK, a total of 17,000 people receive HD for kidney failure, with 5,500 people per year starting treatment for kidney failure, of which 40% receive HD.  On a global scale, as of 2012, there was an estimated 3,010,000 end-stage renal dialysis patients, of which approximately 2,358,000 were undergoing HD or peritoneal dialysis and around 652,000 people were living with kidney transplants. More than 50% of the global dialysis patient population is treated in just five countries – the USA, Japan, China, Brazil and Germany.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.